CPX-351 (Vyxeos) demonstrated improved overall survival (OS) at 5 years versus standard 7+3 chemotherapy in older patients with newly diagnosed, high-risk or secondary acute myeloid leukemia (AML) who achieved a complete response (CR) or a CR with incomplete hematologic recovery (CRi), or who...
Lancet JE, Uy GL, Newell LF, et al. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia:5-year results of a randomised, open-...
Keywords: Acute myeloid leukemia, Chemotherapy, CPX-351, European LeukemiaNet 2017 risk subgroup, Post hoc CPX-351 (Europe: Vyxeos® liposomal; United States: Vyxeos®) is a dual-drug liposomal encapsulation of dau- norubicin and cytarabine in a synergistic 1:5 molar ratio [1]. ...
putting them through induction chemotherapy, and proceeding to a stem cell transplant. Certainly, we want to know that those patients post-transplant are going to continue to do well, and that the relapse rate post-transplant and the survival post-transplant are hopefully improved for patients with...
4. Lancet JE, Uy GL, Newell LF, et al. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised...
"Based on these data, CPX-351 should be considered as the new standard for first-line treatment of older patients with high-risk or secondary AML who are fit for intensive chemotherapy," said Joseph G. Jurcic, MD, professor of medicine at Columbia University Medical Center, in New York City...
CPX-351 (Vyxeos) 是阿糖胞苷和柔红霉素的脂质体封装物,具有潜在的抗肿瘤活性,可用与研究急性髓系白血病。 规格价格库存数量 1 mg ¥ 9,220 现货 5 mg ¥ 18,300 10-14周 大包装 & 定制 TargetMol 的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,...
Keywords: Acute myeloid leukemia, Chemotherapy, CPX-351, European LeukemiaNet 2017 risk subgroup, Post hoc CPX-351 (Europe: Vyxeos® liposomal; United States: Vyxeos®) is a dual-drug liposomal encapsulation of dau- norubicin and cytarabine in a synergistic 1:5 molar ratio [1]. ...
Uy GL, Pullarkat V, Baratam P, et al. Lower-intensity CPX-351 plus venetoclax induction for adults with newly diagnosed AML unfit for intensive chemotherapy. Blood Adv. 2024 Dec 24;8(24):6248-6256. doi: 10.1182/bloodadvances.2024013687. ...
Dr Podoltsev on Blinatumomab Plus Consolidation Chemotherapy in Older BCR-ABL1–Negative ALL Dr Shah on the Rationale for Evaluating Zamto-Cel in R/R DLBCL Dr Kitko on Clinical Outcomes With Axatilimab According to Prior Lines of Therapy for Chronic GVHD ...